Department of Gastroenterology and Hepatology, Westmead Hospital, Westmead, Sydney, New South Wales, Australia.
Clin Gastroenterol Hepatol. 2012 Sep;10(9):969-79. doi: 10.1016/j.cgh.2012.05.020. Epub 2012 May 27.
Most colonic adenomas are ≤ 10 mm and are routinely treated by colonoscopic polypectomy with long-term health benefits. Nonpolypoid lesions ≥ 20 mm, whether sessile or flat and laterally spreading, are forms of advanced mucosal neoplasia that cannot be managed by conventional polypectomy and are often referred for surgery. However, the majority of these lesions when carefully assessed are found to be noninvasive and can be safely and effectively treated by advanced endoscopic techniques including endoscopic mucosal resection or endoscopic submucosal dissection with resultant cost, morbidity, and mortality benefits. Lesion assessment is a critical component. Enhanced imaging methods provide the opportunity for accurate pathological characterization, informing treatment decisions, without the need for previous histologic confirmation. Techniques of advanced endoscopic resection are still in evolution and further improvements, including hybrid techniques, bringing less technically challenging and shorter procedures with superior safety can be reasonably expected in the next decade. Safety is a fundamental consideration. Methods of early recognition of complications, risk stratification, and management pathways are being developed and refined. Standardization, validation, and adoption of these technological developments will improve endoscopic interpretation and therapy and in combination with an increased understanding of adenoma molecular biology, will result in a progressively more individualized lesion-specific endoscopic approach. The future of advanced endoscopic resection in the colon is promising, and the next few years should see the boundaries of endoscopic resection expand well beyond the limits of what we know today.
大多数结肠腺瘤的直径≤10mm,通常通过结肠镜下息肉切除术进行治疗,可长期获益。直径≥20mm 的无蒂病变,无论是息肉样还是扁平状、侧向扩展,均属于高级黏膜肿瘤的形式,不能通过常规息肉切除术进行处理,通常需要转外科治疗。然而,当仔细评估这些病变时,大多数为非侵袭性病变,可以通过先进的内镜技术(包括内镜黏膜切除术或内镜黏膜下剥离术)安全有效地治疗,从而降低成本、减少发病率和死亡率。病变评估是一个关键组成部分。增强成像方法提供了准确的病理特征分析机会,有助于治疗决策,而无需先前的组织学确认。高级内镜切除技术仍在不断发展,在未来十年中,有望进一步改进,包括混合技术,使技术要求更低、程序更短、安全性更高。安全性是一个基本的考虑因素。正在开发和完善识别并发症、风险分层和管理途径的方法。这些技术发展的标准化、验证和采用将提高内镜解读和治疗水平,并结合对腺瘤分子生物学的进一步了解,将导致针对特定病变的内镜治疗方法更加个体化。结肠高级内镜切除术的未来前景广阔,在未来几年中,内镜切除术的范围有望远远超出我们今天所知的范围。